Navigation Links
American Association for Cancer Research (AACR) Deploys Collexis' Reviewer Finder and Journal Dashboard Applications
Date:2/18/2009

Reviewer Finder to Speed up the Peer Review Process!

COLUMBIA, S.C., Feb. 18 /PRNewswire-FirstCall/ -- Collexis Holdings Inc. (OTC Bulletin Board: CLXS), a leading developer of semantic search and knowledge discovery software, announced today that the American Association for Cancer Research (AACR) has licensed the Collexis' Reviewer Finder and Journal Dashboard applications for the 6 AACR cancer research journals.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090107/CLW051LOGO )

"The Collexis Review Finder application will certainly enhance and improve our peer review process as we continuously strive to target the most appropriate reviewers", stated Diane Scott-Lichter, Publisher of AACR. "The Journal Dashboard will provide us with key insights concerning the positioning of our journals in the area of cancer research."

"Having the AACR to sign up for our Reviewer Finder application is quite gratifying for us since AACR is the first society to adopt the Reviewer Finder for the publishing process - until today most of the Reviewer Finder customers were other funding organizations like the NHLBI at the NIH and the Wellcome Trust," said Christian Herzog, MD, Managing Director of the Collexis STM Business Unit. "As the AACR begins to use the Journal Dashboards as journal portfolio analysis tools, we are very confident that it will help them to sharpen the profile of their journals."

The Collexis Reviewer Finder helps publishing organizations in two very important ways: first it assists in reducing the time to identify the most qualified reviewers from hours to virtually minutes by automatically suggesting best matching reviewers for a manuscript, secondly it enhances security by identifying potential conflicts of reviewers based on co-authorship and institutional affiliation. The Collexis Reviewer Finder will be integrated into the publishing workflow solution that AACR is using.

The Collexis Journal Dashboard is providing the customer a complex view to analyze the portfolio of a journal, to compare it on a granular basis to others, to understand author patterns and emerging trends - providing insights for strategic decisions on positioning and further development.

About Collexis Holdings, Inc.

Collexis Holdings, Inc., a leading developer of semantic search and knowledge discovery software is headquartered in Columbia, South Carolina (USA) with operations in Cincinnati, Ohio and Cologne, Germany. Collexis now offers the world's first pre-populated scientific social network for life science researchers, www.biomedexperts.com. Collexis' proprietary technology builds conceptual profiles of text, called Fingerprints, from documents, Websites, emails and other digitized content and matches them with a comprehensive list of pre-defined "fingerprinted" concepts to make research results more relevant and efficient. This matching of concepts eliminates the ambiguity and lack of priority associated with word searches. The results are often described as "finding needles in many haystacks." Through this novel approach, Collexis can build unique applications to search, index and aggregate information as well as prioritize, trend and predict data based on sources in multiple industries without the limitations of language or dialect. Collexis' current clients in the public, private and academic sectors include the Mayo Clinic; Johns Hopkins University; Dana-Farber Cancer Institute, the University of California, San Francisco; the University of South Carolina; Erasmus University Library; Bristol-Myers Squibb; Lockheed Martin; the World Health Organization; Wellcome Trust; the National Institutes of Health; and the U.S. Department of Defense. Shares of Collexis common stock are traded under the symbol CLXS on the OTC Bulletin Board (OTC BB). For more information, visit www.collexis.com.

Forward-Looking Statements

Some of the statements made in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's current expectations and include known and unknown risks, uncertainties and other factors, many of which the company is unable to predict or control, that may cause the company's actual results or performance to differ materially from any future results or performance expressed or implied by such forward-looking statements. These statements involve risks and uncertainties, including risks and uncertainties associated with the company's collaboration with the American Association for Cancer Research. These risks and uncertainties are in addition to other factors detailed from time to time in the company's filings with the SEC, including the section entitled "Risk Factors" in its transition report on Form 10-K for the period ended June 30, 2008. The company cautions investors that any forward-looking statements made by the company are not necessarily indicative of future performance. The company is not responsible for updating the information contained in this press release beyond the published date, or for changes made to this document by wire services or Internet services.


'/>"/>
SOURCE Collexis Holdings Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. American Institute for Medical and Biological Engineering Appoints Dr. Gualberto Ruano to College of Fellows
2. BioIQ Supports American Heart Month to Raise Awareness About Heart Disease, the #1 Killer of Women
3. New General Manager, Transition to New Raleigh Offices Highlight Datatrials Expansion of North American Operations
4. ERYtech Pharma Signs an Agreement With the Penn Jersey Region of American Red Cross
5. American Oriental Bioengineering to Participate in the 2009 UBS Greater China Conference
6. American Oriental Bioengineering Comments on Recent Property Purchase
7. Tips from the journals of the American Society for Microbiology
8. Elsevier Introduces The American Journal of Medicine Blog
9. The American Ceramic Society releases new ACerS-NIST phase equilibria diagrams CD-ROM database
10. Transgenomic Receives Accreditation From College of American Pathologists
11. Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... 16, 2017 , ... Today, 3Bar Biologics Inc ., ... in funding from an impressive group of investors, including Rev1 Ventures, Maumee Ventures, ... this investment, 3Bar is broadening availability of its groundbreaking offering that uses naturally ...
(Date:8/16/2017)... year,s edition of the Inc. 5000 features a now-familiar name: BioPoint ( ... the list for the third year in a row. Now in its ... on a set of quantitative metrics. In addition, BioPoint was also named ... Bay State . ... 5000 ...
(Date:8/15/2017)... -- After spending the past two years building a state-of-the-art technology ... now offers this platform to healthcare stakeholders (hospitals, foundations, biopharma companies ... data collection vis a vis their members, under their own brand. ... this offer. ... ...
(Date:8/15/2017)... CA (PRWEB) , ... August 15, 2017 , ... ... pioneering graphene biosensors that accelerate pharmaceutical and biotherapeutics development, announces the launch of ... number of steps needed to gain kinetic binding data for a wide range ...
Breaking Biology Technology:
(Date:4/17/2017)... , April 17, 2017 NXT-ID, Inc. ... company, announces the filing of its 2016 Annual Report on Form ... Exchange Commission. ... Form 10-K is available in the Investor Relations section of the ... on the SEC,s website at http://www.sec.gov . 2016 ...
(Date:4/11/2017)... N.Y. , April 11, 2017 ... fingerprints, but researchers at the New York University ... College of Engineering have found that partial similarities ... security systems used in mobile phones and other ... thought. The vulnerability lies in the ...
(Date:4/5/2017)... -- KEY FINDINGS The global market for ... of 25.76% during the forecast period of 2017-2025. The ... the growth of the stem cell market. ... INSIGHTS The global stem cell market is segmented on ... stem cell market of the product is segmented into ...
Breaking Biology News(10 mins):